Fibroblast activation protein-α in fibrogenic disorders and cancer: more than a prolyl-specific peptidase?

Expert Opinion on Therapeutic Targets

Volumn 21, Issue 10, 2017, Pages 977-991

  Juillerat Jeanneret, Lucienne ^a,b   Tafelmeyer, Petra ^c,d   Golshayan, Dela ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY INSTITUTE OF PATHOLOGY   (Switzerland)

^c Hybrigenics SA   (France)

^d Hybrigenics Corporation   (United States)

Author keywords

Cancer; FAP ; fibroblast activation protein ; fibrosis; inflammation; inhibitors; therapy

Indexed keywords

DIPEPTIDYL PEPTIDASE 10; DIPEPTIDYL PEPTIDASE 6; DIPEPTIDYL PEPTIDASE 8; DIPEPTIDYL PEPTIDASE 9; DIPEPTIDYL PEPTIDASE IV; EXOPEPTIDASE; PEPTIDE HYDROLASE; PROLYL ENDOPEPTIDASE; SEPRASE; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; GELATINASE; MEMBRANE PROTEIN; SERINE PROTEINASE;

ENZYME ACTIVITY; ENZYMOLOGY; FIBROBLAST; FIBROSIS; GENE DELETION; GENE REPRESSION; HUMAN; IMMUNOTHERAPY; MALIGNANT NEOPLASM; MYOFIBROBLAST; NONHUMAN; PROTEIN EXPRESSION; REVIEW; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE COURSE; DRUG DESIGN; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PATHOLOGY;

ANIMALS; DISEASE PROGRESSION; DRUG DESIGN; FIBROBLASTS; FIBROSIS; GELATINASES; GENE EXPRESSION REGULATION; HUMANS; MEMBRANE PROTEINS; MOLECULAR TARGETED THERAPY; NEOPLASMS; SERINE ENDOPEPTIDASES;

EID: 85029496591     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1080/14728222.2017.1370455     Document Type: Review

References (174)

1. Eddy AA., Overview of the cellular and molecular basis of kidney fibrosis. Kidney Int Suppl. 2014;4:2–8.
2. Rockey DC, Bell PD, Hill JA., Fibrosis-a common pathway of organ injury and failure. New Eng J Med. 2015;372:1138–1149.
3. Wynn TA, Ramalingam TR. Mechanisms of fibrosis:therapeutic translation for fibrotic disease. Nature Med. 2012;18:1028–1040.
4. Denys H, Derycke L, Hendrix A, et al. Differential impact of TGFβ and EGF on fibroblast differentiation and invasion reciprocally promotes colon cancer cell invasion. Cancer Lett. 2008;266:263–274.
5. Gauldie J, Bonniaud P, Sime P, et al. TGF-β, Smad3 and the process of progressive fibrosis. Biochem Soc Trans. 2007;35:661–664.
6. Kraman R, DiRocco DP, Humphreys BD. Understanding the origin, activation and regulation of matrix-producing myofibroblasts for the treatment of fibrotic diseases. J Pathol. 2013;231:273–289.
7. Brennen WN, Isaacs JT, Denmeade SR. Rationale behind targeting fibroblast activation protein-expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy. Mol Cancer Ther. 2012;11:257–266.
8. Adhyatmika A, Putri KSS, Beljaars L, et al. The elusive antifibrotic macrophage. Front Med. 2015;2:81.
9. Waumans Y, Baerts L, Kehoe K, et al. The dipeptidyl peptidase family, prolyl oligopeptidase, and prolyl carboxypeptidase in the immune system and inflammatory disease, including atherosclerosis. Frontiers Immunol. 2015;6:387.
10. Busek P, Malík R, Sedo A. Dipeptidyl peptidase IV activity and/or structure homologues (DASH) and their substrates in cancer. Int J Biochem Cell Biol. 2004;36:408–421.
11. Chen WT, Kelly T, Ghersi G. DPPIV, seprase and related serine peptidases in multiple cellular functions. Current Topics Dev Biol. 2003;54:207–232.
12. Polgár L. The prolyl oligopeptidase family. Cell Mol Life Sci. 2002;59:349–362.
13. Rosenblum JS, Kozarich JW. Prolyl peptidases:a serine protease subfamily with high potential in drug discovery. Curr Op Chem Biol. 2003;7:496–504.
14. Cunningham DF, O’Connor B. Proline specific peptidases. Biochim Biophys Acta. 1997;1343:160–186.
15. Sedo A, Malík R. Dipeptidyl peptidase IV-like molecules:homologous proteins or homologous activities. Biochem Biophys Acta. 2001;1550:107–116.
16. Park JE, Lenter MC, Zimmermann RN, et al. Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts. J Biol Chem. 1999;274:36505–36512.• One of the first paper discussing the dual exo- and endopeptidase activities and the location in the tumor stroma of FAP-α.
17. Giannandrea M, Parks WC. Diverse functions of matrix metalloproteinases during fibrosis. Dise Mod Mech. 2014;7:193–203.
18. Rea D, Fülöp V. Structure-functions properties of prolylendopeptidase family enzymes. Cell Biochem Biophys. 2006;44:349–365.
19. Engel M, Hoffmann T, Wagner L, et al. The crystal structure of dipeptidyl peptidase IV (CD26) reveals its functional regulation and enzymatic mechanisms. Proc Nat Acad Sci USA. 2003;100:5063–5068.
20. Rasmussen HB, Branner S, Wiberg FC, et al. Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog. Nat Struct Biol. 2003;10:19–25.
21. Juillerat-Jeanneret L. Dipeptidyl peptidase IV and its inhibitors:therapeutics for type 2 diabetes and what else? J Med Chem. 2014;57:2197–2212.
22. De Meester I, Lambeir AM, Proost P, et al. Dipeptidyl peptidase IV substrates. Adv Exp Med Biol. 2003;524:3–17.
23. Hiramatsu H, Yamamoto A, Kyono K, et al. The crystal structure of human dipeptidyl peptidase IV (DPPIV) complex with diprotin A. J Biol Chem. 2004;385:561–564.
24. Oefner C, D’Arcy A, Mac Sweeney A, et al. High-resolution structure of human apo dipeptidyl peptidase IV/CD26 and its complex with 1-[({2-[85-iodopyridin-2-yl)aminoethyl}aminoacetyl]-2-cyano-(S)-pyrrolodine. Acta Crystallogr. 2003;D59:1206–1212.
25. Thoma R, Löffler B, Stihle M, et al. Structural basis of proline-specific exopeptidase activity as observed in human dipeptidyl peptidase IV. Structure. 2003;11:947–959.
26. Fleischer B. CD26:a surface protease involved in T-cell activation. Immunol Today. 1994;15:180–184.
27. Bogenrieder T, Finstad CL, Freeman RH, et al. Expression and localization of aminopeptidase A, aminopeptidase N, and dipeptidyl peptidase IV in benign and malignant human prostate tissue. Prostate. 1997;33:225–232.
28. Berger Y, Chapuis Bernasconi C, Neier R, et al. Determination of intracellular prolyl/glycyl-specific proteases in intact living human cells using protoporphyrin IX production as a reporter system. ChemBiol. 2005;12:867–872.
29. Asada Y, Aratake Y, Kotani T, et al. Expression of dipeptidyl aminopeptidase IV activity in human lung carcinoma. Histopathology. 2003;23:265–270.
30. Mentlein R, Hattermann K, Hemion C, et al. Expression and role of the cell surface protease seprase/fibroblast activation protein-alpha (FAP-alpha) in astroglial tumors. Biol Chem. 2011;392:199–207.
31. Cheng HC, Abdel-Ghany M, Elble RC, et al. Lung endothelial dipeptidylpeptidase IV promotes adhesion and metastasis of rat breast cancer cells via tumor-cell associated fibronectin. J Biol Chem. 1998;273:2407–2415.
32. Lawandi J, Gerber-Lemaire S, Juillerat-Jeanneret L, et al. Inhibitors of prolyl oligopeptidases for the therapy of human diseases:defining diseases and inhibitors. J Med Chem. 2010;53:3423–3438.
33. Fülöp V, Böcskei Z, Polgár L. Prolyl oligopeptidase:an unusual β-propeller domain regulates proteolysis. Cell. 1998;94:161–170.• A paper describing the basic enzymatic mechanisms of prolyl-oligopeptidases.
34. Savolainen MH, Yan X, Myohanen TT, et al. Prolyl oligopeptidase enhances alpha-synuclein dimerization via direct protein-protein interaction. J Biol Chem. 2015;290:5117–5126.
35. O’Leary RM, Gallagher SP, O’Connor B. Purification and characterization of a novel membrane-bound form of prolyl endopeptidase in bovine brain. Int J Biochem Cell Biol. 1996;28:441–449.
36. Fuxreiter M, Magyar C, Juhász T, et al. Flexibility of prolyl oligopeptidase:molecular dynamics and molecular framework analysis of the potential substrate pathways. Proteins. 2005;60:504–512.
37. Venäläinen JI, Juvonen RO, Forsberg MM, et al. Substrate-dependent, non-hyperbolic kinetics of pig brain prolyl oligopeptidase and its tight binding inhibition by JTP-4819. Biochem Pharm. 2002;64:463–471.
38. Kaszuba K, Rög T, Danne R, et al. Molecular dynamics, crystallography and mutagenesis studies on the substrate gating mechanism of prolyl oligopeptidase. Biochimie. 2012;94:1398–1411.
39. Underwood R, Chiravuri M, Lee H, et al. Sequence, purification and cloning of an intracellular serine protease, quiescent cell proline dipeptidase. J Biol Chem. 1999;274:34053–34058.
40. Maes MB, Lambeir AM, Gilany K, et al. Kinetic investigation of human dipeptidyl peptidase II (DPPII)-mediated hydrolysis of dipeptide derivatives and its identification as quiescent cell proline dipeptidase QPP/dipeptidyl peptidase 7 (DPP7). Biochem J. 2005;386:315–324.
41. Chiravuri M, Agarraberes F, Mathieu SL, et al. Vesicular localization and characterization of a novel post-proline cleaving aminodipeptidase, quiescent cell proline dipeptidase. J Immunol. 2000;165:5695–5702.
42. Abbott CA, Yu DM, Woollatt E, et al. Cloning, expression and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog, DPP8. Eur J Biochem. 2000;267:6140–6150.
43. Ajami K, Abbott CA, McCaughan GW, et al. Dipeptidyl peptidase 9 has two forms, a broad tissue distribution, cytoplasmic localization and DPIV-like peptidase activity. Biochim Biophys Acta. 2004;1679:18–28.
44. Olsen C, Wagtmann N. Identification and characterization of human DPP9, a novel homologue of dipeptidyl peptidase IV. Gene. 2002;299:185–193.
45. Yu DMT, Yao TW, Chowdury S, et al. The dipeptidyl peptidase IV family in cancer and cell biology. FEBS Lett. 2010;277:1126–1144.
46. Zhu H, Zhou ZM, Lu L, et al. Expression of a novel dipeptidyl peptidase 8 (DPP8) transcript variant, DPP8-v3, in human testis. Asian J Androl. 2005;7:245–255.
47. Waumans Y, Vliegen G, Maes L, et al. The dipeptidyl peptidases 4, 8 and 9 in mouse monocytes and macrophages:DPP8/9 inhibition attenuates M1 macrophages activation in mice. Inflammation. 2015;39:413–424.
48. Kaulin YA, De Santiago-Castillo JA, Rocha CA, et al. The dipeptidyl-peptidase-like protein DPP6 determines the unitary conductance of neuronal Kv4.2 channels. J Neurosci. 2009;29:3242–3251.
49. SA-like properties. J Physiol. 2005;568:767–788.
50. Piñeiro-Sánchez ML, Goldstein LA, Dodt J, et al. Identification of the 170-kDa melanoma membrane-bound gelatinase (seprase) as a serine integral membrane protease. J Biol Chem. 1997;272:7595–7601.• Initial description of the activated fibroblast marker FAP as a prolyl-specific serine protease.
51. Rettig WJ, Su SL, Fortunato SR, et al. Fibroblast activation protein:purification, epitope mapping and induction by growth factors. Int J Cancer. 1994;58:385–392.
52. Scanlan MJ, Raj BK, Calvo B, et al. Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers. Proc Natl Acad Sci USA. 1994;91:5657–5661.
53. Goldstein LA, Ghersi G, Piñeiro-Sánchez ML, et al. Molecular cloning of seprase:a serine integral membrane protease from human melanoma. Biochim Biophys Acta. 1997;1361:11–19.• Initial description of FAP-α as a prolyl-specific serine protease.
54. Chen WT, Kelly T. Seprase complex in cellular invasiveness. Cancer Metastasis Rev. 2003;22:259–269.
55. Chen WT. DPPIV and seprase in cancer invasion and angiogenesis. Adv Exp Med Biol. 2003;524:197–203.
56. Kelly T. Evaluation of seprase activity. Clin Exp Metas. 1999;17:57–62.
57. Kelly T, Huang Y, Simms AE, et al. Fibroblast activation protein-α:a key modulator of the microenvoronment of multiple pathologies. Int Rev Cell Mol Biol. Vol. 297. 2012. pp. 83–116.
58. Gass J, Khosla C. Prolyl endopeptidases. Cell Mol Life Sci. 2007;64:345–355.
59. Aertgeerts K, Levin I, Shi L, et al. Structural and kinetic analysis of the substrate specificity of human fibroblast activation protein alpha. J Biol Chem. 2005;280:19441–19444.•• An important paper describing the enzymatic mechanisms of FAP-α for further design of inhibitors.
60. Aoyama A, Chen WT. A 170-kDa membrane-bound protease is associated with the expression of invasiveness by human malignant melanoma cells. Proc Natl Acad Sci USA. 1990;7:8296–8300.
61. Edosada CY, Quan C, Wiesman C, et al. Selective inhibition of fibroblast activation protein protease based on dipeptide substrate. J Biol Chem. 2006;281:7437–7442.•• An important paper describing the inhibition mechanisms of FAP-α.
62. Edosada CY, Quan C, Tran T, et al. Peptide substrate profiling defines fibroblast activation protein as an endopeptidase of strict Gly(2)-Pro(1)-cleaving specificity. FEBS Lett. 2008;580:1581–1586.•• An important paper describing the substrate specificity mechanisms of FAP-α and for further design of inhibitors.
63. Balaziova E, Busek P, Stremenova J, et al. Coupled expression of dipeptidyl peptidase-IV and fibroblast activation protein-α in transformed astrocytic cells. Mol Cell Biochem. 2011;354:283–289.
64. Mathew S, Scanlan MJ, Mohan Raj BK, et al. The gene for fibroblast activation protein alpha (FAP), a putative cell surface-bound serine protease expressed in cancer stroma and wound healing, maps to chromosome band 2q23. Genomics. 1995;25:335–337.
65. Ghersi G, Zhao Q, Salamone M, et al. The protease complex consisting of dipeptidyl peptidase IV and seprase plays a role in the migration and invasion of human endothelial cells in collagenous matrices. Cancer Res. 2006;66:4652–4661.
66. Ghersi G, Dong H, Goldstein LA, et al. Regulation of fibroblast migration on collagenous matrix by a cell surface peptidase complex. J Biol Chem. 2002;277:29231–29241.
67. 657 and conserved active site residues promote fibroblast activation protein endopeptidase activity via distinct mechanisms of transition state stabilization. Biochemistry. 2007;46:4598–4605.•• An important paper describing the amino acids involved in the enzymatic mechanisms of FAP-α or further design of inhibitors.
68. Wang XM, Yu DM, McCaughan GW, et al. Fibroblast activation protein increases apoptosis, cell adhesion, and migration by the LX-2 human stellate cell line. Hepatology. 2005;42:935–945.
69. Tran T, Quan C, Edosada CY, et al. Synthesis and structure-activity relationship of N-acyl-Gly-, N-acyl-Sar- and N-blocked-boroPro inhibitors of FAP, DPP4, and POP. Bioorg Med Chem Lett. 2007;17:1438–1442.•• An important paper comparing the binding of inhibitors by three members of the DASH family, DPP IV, POP, and FAP-α, for further design of FAP-α specific inhibitors.
70. Kaushik S, Sowdhamini R. Structural analysis of prolyl oligoopeptidases using molecular docking and dynamics:insights into conformational changes and ligand binding. PloS One. 2011;6:e26251.
71. Tang HK, Chen KC, Liou GG, et al. Role of propeller loop in the quaternary structure and enzymatic activity of prolyl dipeptidases DPP IV and DPP9. FEBS Lett. 2011;585:3409–3414.
72. Osborne B, Yao TW, Wang XM, et al. A rare variant in human fibroblast activation protein associated with ER stress, loss of enzymatic function and loss of cell surface localisation. Biochim Biophys Acta. 2014;1844:1248–1259.• Description of an intracellular form of FAP-α.
73. Lee KN, Jackson KW, Christiansen VJ, et al. Antiplasmin-cleaving enzyme is a soluble form of fibroblast activation protein. Blood. 2006;107:1397–1404.
74. Levy MT, McCaughan GW, Abbott CA, et al. Fibroblast activation protein:a cell surface dipeptidyl peptidase and gelatinase expressed by stellate cells at the tissue remodelling interface in human cirrhosis. Hepatology. 1999;29:1768–1778.
75. Bauer S, Jendro MC, Wadle A, et al. Fibroblast activation protein is expressed by rheumatoid myofibroblast-like synoviocytes. Arthritis Res Ther. 2006;8:R171–R171.
76. Keane FM, Yao TW, Seelk S, et al. Quantitation of fibroblast activation protein (FAP)-specific protease activity in mouse, baboon and human fluids and organs. FEBS Open Biol. 2013;4:43–54.
77. Goldstein LA, Chen WT. Identification of an alternatively spliced seprase mRNA that encodes a novel intracellular isoform. J Biol Chem. 2000;275:2554–2559.• Initial description of an intracellular form of FAP-α.
78. Xia Q, Zhang FF, Geng F, et al. Anti-tumor effects of DNA vaccine targeting human fibroblast activation protein alpha by producing specific immune responses and altering tumor microenvironment in the 4T1 murine breast cancer model. Cancer Immunol. Immunother. 2016;65:613–624.
79. Yang X, Lin Y, Shi Y, et al. FAP promotes immunosuppression by cancer-associated fibroblasts in the tumor microenvironment via STAT3–CCL2 signaling. Cancer Res. 2016;76:4124–4135.
80. Hamson EJ, Keane FM, Tholen S, et al. Understanding fibroblast activation protein (FAP):substrates, activities, expression and targeting for cancer therapy. Proteomics Clin Appl. 2014;8:454–463.
81. Keane FM, Nadvi NA, Yao TW, et al. Neuropeptide Y, B-type natriuretic peptide, substance P and peptide YY are novel substrates of fibroblast activation protein-alpha. Febs J. 2011;278:1316–1332.
82. Lee KN, Jackson KW, Christiansen VJ, et al. A novel plasma proteinase potentiates alpha2-antiplasmin inhibition of fibrin digestion. Blood. 2004;103:3783–3788.
83. Koczorowska MM, Tholen S, Bucher F, et al. Fibroblast activation protein-α, a stromal cell surface protease, shapes key features of cancer associated fibroblasts through proteome and degradome alterations. Mol Oncol. 2016;10:40–58.
84. Coppage AL, Heard KR, DiMare MT, et al. Human FGF21 is a substrate of fibroblast activation protein. PLOS One. 2016;11:e0151269.
85. Dunshee DR, Bainbridge TW, Kljavin NM, et al. Fibroblast activation protein cleaves and inactivates fibroblast growth factor 21. J Biol Chem. 2016;291:5986–5996.
86. Zhen EY, Jin Z, Ackermann BL, et al. Circulating FGF21 proteolytic processing mediated by fibroblast activation protein. Biochem J. 2016;473:605–614.
87. Aggarwal S, Brennen WN, Kole TP, et al. Fibroblast activation protein peptide substrates identified from human collagen I derived gelatin cleavage sites. Biochemistry. 2008;47:1076–1086.
88. Mazur A, Holthoff E, Vadali S, et al. Cleavage of type I collagen by fibroblast activation protein-alpha enhances class A scavenger receptor mediated macrophage adhesion. PLoS ONE. 2016;11:e0150287.
89. Huang CH, Suen CS, Lin CT, et al. Cleavage-site specificity of prolyl endopeptidase FAP investigated with a full-length protein substrate. J Biochem. 2011;149:685–692.
90. Brokopp CE, Schoenauer R, Richards P, et al. Fibroblast activation protein is induced by inflammation and degrades type I collagen in thin-cap fibroatheromata. Eur Heart J. 2011;32:2713–2722.
91. Fan MH, Zhu Q, Li HH, et al. Fibroblast activation protein (FAP) accelerates collagen degradation and clearance from lungs in mice. J Biol Chem. 2016;291:8070–8089.
92. Cavasin MA, Rhaleb NE, Yang XP, et al. Prolyl oligopeptidase is involved in release of the anti-fibrotic peptide Ac-SDKP. Hypertension. 2004;43:1140–1145.
93. Sosne G, Qiu P, Goldstein AL, et al. Biological activities of thymosin β4 defined by active sites in short peptide sequences. Faseb J. 2010;24:2144–2151.
94. Zuo Y, Chun B, Potthoff SA, et al. Thymosin β4 and its degradation product, Ac-SDKP, are novel reparative factors in renal fibrosis. Kid Int. 2013;84:1166–1175.
95. Kanasaki K, Shi S, Kanasaki M, et al. Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen. Diabetes. 2014;63:2120–2131.
96. Kanasaki K, Nagai T, Nitta K, et al. N-acetyl-seryl-aspartyl-lysyl-proline:a valuable endogenous anti-fibrotic peptide for combating kidney fibrosis in diabetes. Front Pharm. 2014;5:70.
97. Hahn CS, Scott DW, Xu X, et al. The matrikine N-α-PGP couples extracellular matrix fragmentation to endothelial permeability. Sci Adv. 2015;e1500175.
98. Gaggar A, Jackson PL, Noerager BD, et al. A novel proteolytic cascade generates an extracellular matrix-derived chemoattractant in chronic neutrophilic inflammation. J Immunol. 2008;180:5662–5669.
99. Wells JM, Jackson PL, Viera L, et al. A randomized placebo-controlled trial of roflumistat. Effect on proline-glycine-proline and neutrophilic inflammation in chronic obstructive pulmonary disease. Am J Resp Crit Care Med. 2015;192:934–942.
100. Poplawski SE, Lai JH, Sanford DG, et al. Pro-Soft Val-boroPro:a strategy for enhancing in vivo performance of boronic acid inhibitors of serine proteases. J Med Chem. 2011;54:2022–2028.
101. Li J, Chen K, Liu H, et al. An activatable near infrared probe for in vivo imaging of fibroblast activation protein alpha. Bioconj Chem. 2012;23:1704–1711.
102. Lo PC, Chen J, Stefflova K, et al. Photodynamic molecular beacon triggered by fibroblast activation protein on cancer-associated fibroblasts for diagnosis and treatment of epithelial cancers. J Med Chem. 2009;52:358–368.
103. Milo LJ, Lai JH, Wu W, et al. Chemical and biological evaluation of dipeptidyl boronic acid proteasome inhibitors for use in prodrugs and pro-soft drugs targeting solid tumors. J Med Chem. 2011;54:4365–4377.
104. Huang S, Fang R, Xu J, et al. Evaluation of the tumor targeting of FAPα-based doxorubicin prodrug. J Drug Target. 2011;19:487–496.
105. Zhang Y, Zhang X, Liu H, et al. Mixed nanomicelles as potential carriers for systemic delivery of Z-GP-Dox, an FAPα-based doxorubicin prodrug formulation and pharmacokinetic evaluation. Int J Nanomed. 2015;10:1625–1636.
106. Brennen WN, Rosen DM, Aggarwal S, et al. Targeting carcinoma-associated fibroblasts within the tumor stroma with a fibroblast activation protein-activated prodrug. J Natl Cancer Inst. 2012;104:1320–1324.
107. LeBeau AM, Brennen N, Aggarwal S, et al. Targeting the cancer stroma with a fibroblast activation protein-activated promelittin protoxin. Mol Cancer Ther. 2009;8:1378–1386.
108. Passemard S, Staedler D, Sonego G, et al. Functionalized bismuth ferrite harmonic nanoparticles for cancer cells labeling and imaging. J Nanopart Res. 2015;17:414–427.
109. Jackson KW, Christiansen VJ, Yadav VR, et al. Suppression of tumor growth in mice by rationally designed pseudopeptide inhibitors of fibroblast activation protein and prolyl oligopeptidase. Neoplasia. 2015;17:43–54.
110. Aimes RT, Zijlstra A, Hooper JD, et al. Endothelial cell serine proteases expressed during vascular morphogenesis and angiogenesis. Thromb Haemost. 2003;89:561–572.
111. Ariga N, Sato E, Ohuchi N, et al. Stromal expression of fibroblast activation protease/seprase, a cell membrane serine proteinase and gelatinase, is associated with longer survival in patients with invasive ductal carcinoma of breast. Int J Cancer. 2001;95:67–72.
112. Huber MA, Kraut N, Park JE, et al. Fibroblast activation protein:differential expression and serine protease activity in reactive stromal fibroblasts of melanocytic skin tumors. J Invest Dermato. 2003;120:182–188.
113. Huang Y, Simms AE, Mazur A, et al. Fibroblast activation protein-α promotes tumor growth and invasion of breast cancer cells through non-enzymatic functions. Clin Exp Metastasis. 2011;28::567–579.
114. Huang Y, Wang S, Kelly T. Seprase promotes rapid tumor growth and increased microvessel density in a mouse model of human breast cancer. Cancer Res. 2004;64:2712–2716.
115. Morrison ME, Vijayasaradhi S, Engelstein D, et al. A marker for neoplastic progression of human melanocytes is a cell surface ectopeptidase. J Exp Med. 1993;177:1135–1143.
116. Scott AM, Wiseman G, Welt S, et al. A phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res. 2003;9:1639–1647.• Clinical trial evaluating the anticancer properties of aa anti-FAP-α antibody.
117. Kelly T, Kechelava S, Rozypal TL, et al. Seprase, a membrane-bound protease, is overexpressed by invasive ductal carcinoma cells of human breast cancer. Mod Pathol. 1998;11:855–863.
118. Santos AM, Jung J, Aziz N, et al. Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice. J Clin Invest. 2009;119:3613–3625.• A paper evaluating in detail the anticancer properties of targeting FAP-α.
119. Iwasa S, Jin X, Okada K, et al. Increased expression of seprase, a membrane-type serine protease, is associated with lymph node metastasis in human colorectal cancer. Cancer Lett. 2003;199:91–98.
120. Okada K, Chen WT, Iwasa S, et al. Seprase, a membrane-type serine protease, has different expression patterns in intestinal- and diffuse-type gastric cancer. Oncology. 2004;65:363–370.
121. Goodman JD, Rozypal TL, Kelly T. Seprase, a membrane-bound protease, alleviates the serum growth requirement of human breast cancer cells. Clin Exp Metastasis. 2000;26:459–470.
122. Roberts EW, Magiera L, Jones JO, et al. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-α. Science. 2010;330:827–830.•• An important paper demonstrating that the elimination of the protein FAP-α has anticancer properties.
123. Wang XM, Yao TW, Nadvi NA, et al. Fibroblast activation protein and chronic liver disease. Front Biosci. 2008;13:3168–3180.
124. Artym VV, Kindzelskii AL, Chen WT, et al. Molecular proximity of seprase and the urokinase-type plasminogen activator receptor on malignant melanoma cell membranes:dependence on beta1 integrins and the cytoskeleton. Carcinogenesis. 2002;23:1593–1601.
125. Monsky WL, Lin CY, Aoyama A, et al. A potential marker protease of invasiveness, seprase, is localized on invadopodia of human malignant melanoma cells. Cancer Res. 1994;54:5702–5710.
126. Mueller SC, Ghersi G, Akiyama SK, et al. A novel protease-docking function of integrin at invadopodia. J Biol Chem. 1999;274:24947–24952.
127. Lee HO, Mullins SR, Franco-Barraza J, et al. FAP-overexpressing fibroblasts produce an extracellular matrix that enhances invasive velocity and directionality of pancreatic cancer cells. BMC Cancer. 2011;11:245.
128. Lee SY, Kim SI, Choi ME. Therapeutic targets for treating fibrotic kidney diseases. Translat Res. 2015;165:512–530.
129. Ghersi G, Dong H, Goldstein LA, et al. Seprase-DPPIV association and prolyl peptidase activities of the protease complex. Adv Exp Med Biol. 2003;524:87–94.
130. Iwata S, Morimoto C. CD26/dipeptidyl peptidase IV in context:the different roles of a multifunctional ectoenzyme in malignant transformation. J Exp Med. 1999;190:301–305.
131. Pro B, Dang NH. CD26/dipeptidyl peptidase IV and its role in cancer. Histol Histopath. 2004;19:1345–1351.
132. Wesley UV, Albino AP, Tiwari S, et al. A role for dipeptidyl peptidase IV in suppressing the malignant phenotype of melanocytic cells. J Exp Med. 1999;190:311–322.
133. Wesley UV, Tiwari S, Houghton AN. Role for dipeptidyl peptidase IV in tumor suppression of human non small cell lung carcinoma cells. Int J Cancer. 2004;109:855–866.
134. Havre PA, Abe M, Urasaki Y, et al. The role of CD26/DPPIV in cancer. Front Biosci. 2008;13:1634–1645.
135. O’Brien P, O’Connor BF. Seprase:an overview of an important matrix serine protease. Biochim Biophys Acta. 2008;784:1130–1145.
136. Kraman M, Bambrough PJ, Arnold JN, et al. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science. 2010;330:827–8830.
137. Cheng JD, Valianou M, Canutescu AA, et al. Abrogation of fibroblast activation protein enzymatic activity attenuates tumor growth. Mol Cancer Ther. 2005;4:351–360.
138. Loeffler M, Kruger JA, Niethammer AC, et al. Targeting tumor-associated fibroblasts improve cancer chemotherayp by increasing intratumoral drug uptake. J Clin Invest. 2006;116:1953–1962.
139. Demuth HU, Schlenzig D, Schierhorn A, et al. Design of (ω-N-(O-acyl)hydroxyamid) aminodicarboxylic acid pyrrolidides as potent inhibitors of proline-specific peptidases. FEBS Lett. 1993;320:23–27.• One of the initial paper designing inhibitors for prolyl peptidases.
140. Racys DT, Rea D, Fülöp V, et al. Inhibition of prolyl oligopeptidase with a synthetic unnatural peptide. Bioorg Med Chem. 2010;18:4775–4782.
141. López A, Tarragó T, Giralt E. Low molecular weight inhibitors of prolyl oligopeptidase:a review of compounds patented from 2003 to 2010. Exp Opin Ther Patents. 2011;21:1023–1044.
142. Ryabtsova O, Jansen K, Van Goethem S, et al. Acylated Gly-(2-cyano)pyrrolidines as inhibitors of fibroblast activation protein (FAP) and the issue of FAP/prolyl oligopeptidase (PREP)-selectivity. Bioorg Med Chem Lett. 2012;22:3412–3417.
143. Jambunathan K, Watson DS, Endsley AN, et al. Comparative analysis of the substrate preferences of two post-proline cleaving endopeptidases, prolyloligopeptidase and fibroblast activation protein alpha. FEBS Lett. 2012;586:2507–2512.
144. Tsai TY, Yeh TK, Chen X, et al. Substituted 4-carboxymethyl-pyroglutamic acid diamides as potent and selective inhibitors of fibroblast activation protein. J Med Chem. 2010;53:6572–6583.
145. Van Goethem S, Matheeussen V, Joossens J, et al. Structure-activity relationship studies of isoindoline inhibitors of dipeptidylpeptidases 8 and 9 (DPP8, DPP9):is DPP8 selectivity an attainable goal. J Med Chem. 2011;54:5737–5746.
146. Gilmore BF, Lynas JF, Scott CJ, et al. Dipeptide proline diphenyl phosphonates are potent, irreversible inhibitors of seprase (FAPα). Biochem Biophys Res Comm. 2006;346:436–446.
147. De Cesco S, Deslandes S, Therrien E, et al. Virtual screening and computational optimization for the discovery of covalent prolyl oligopeptidase inhibitors with activity in human cells. J Med Chem. 2012;55:6306–6315.
148. Poplawski SE, Lai JH, Li Y, et al. Identification of selective and potent inhibitors of fibroblast activation protein and prolyl oligopeptidase. J Med Chem. 2013;56:3467–3477.• One of the initial paper designing inhibitors for FAP-α.
149. Jansen K, Heirbaut L, Verkerk R, et al. Extended structure-activity relationship and pharmacokinetic investigation of (4-quinolinoyl)glycyl-2-cyanopyrrolidine scaffold. ACS Med Chem Lett. 2013;4:491–496.
150. St-Pierre JF, Karttunen M, Mousseau N, et al. Use of umbrella sampling to calculate the entrance/exit pathway for Z-Pro-prolinal of prolyl oligopeptidase. J Chem Theory Comput. 2011;7:1583–1594.
151. Jansen K, De Winter H, Heirbaut L, et al. Selective inhibitors of fibroblast activation protein (FAP) with a xanthine scaffold. Med Chem Commun. 2014;5:1700–1707.•• An important paper designing inhibitors specific for FAP-α.
152. Jansen K, Heirbaut L, Cheng JD, et al. Selective inhibitors of fibroblast activation protein (FAP) with a (4-quinolinoyl)glycyl-2-cyanopyrrolidine inhibitors. J Med Chem. 2014;57:3053−3074.•• An important paper designing inhibitors specific for FAP-α.
153. aa-boroPro dipeptides. J Med Chem. 1996;39:2087–2094.
154. Narra K, Mullins SR, Lee HO, et al. Phase II trial of single agent Val-boroPro (talabostat) inhibiting fibroblast activation protein in patients with metastatic colorectal cancer. Cancer Biol Ther. 2007;6:1691–1699.
155. Nemunaitis J, Vukelja SJ, Richards D, et al. Phase I of PT-100 (PT-100), a cytokine-inducing small molecules following chemotherapy for solid tumor malignancy. Cancer Invest. 2006;24:553–561.
156. Adams S, Miller GT, Jesson MI, et al. PT-100, a small molecule dipeptidyl peptidase inhibitor, has potent antitumor effects and augments antibody-mediated cytotoxicity via a novel immune mechanism. Cancer Res. 2004;64:5471–5480.
157. Li M, Yin T, Shi H, et al. Targeting of cancer-associated fibroblasts enhances the efficacy of cancer chemotherapy by regulating the tumor microenvironment. Mol Med Reports. 2016;13:2476–2484.
158. Uprichard MJ, O’Day SJ, Pavlick AC, et al. Phase 2 study of talabostat and cisplatin in stage IV melanoma. J Clin Oncol. 2005;23:725s.
159. Cunningham C, Pavlick AC, Khan KD, et al. Phase 2 trial of talabostat and cisplatin in patients with stage IV melanoma. J Clin Oncol. 2006;24:462s.•• An important paper describing clinical trials targeting the anticancer properties of a FAP-α inhibitor.
160. Redman BG, Ernstoff MS, Gajewski TF, et al. Phase 2 clinical trial of talabostat in stage IV melanoma. J Clin Oncol. 2005;23:727s.
161. Welt S, Divgi CR, Scott AM, et al. Antibody targeting in metastatic colon cancer:a phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts. J Clin Oncol. 1994;12:1193–1203.•• An important paper describing the anticancer effect of eliminating the protein FAP-α in a clinical trial.
162. Cheng JD, Dunbrack RL, Valianou M, et al. Promotion of tumor growth by murine fibroblast activation protein, a serine protease in an animal model. Cancer Res. 2002;62:4767–4772.
163. Hofheinz RD, al-Batran SE, Hartmann F, et al. Stromal antigen targeting by a humanised monoclonal antibody:an early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer. Onkologie. 2003;26:44–46.
164. Teichgräber V, Monasterio C, Chaitanya K, et al. Specific inhibition of fibroblast activation protein (FAP)-alpha prevents tumor progression in vitro. Adv Med Sci. 2015;60:264–272.
165. Ostermann E, Garin-Chesa P, Heider KH, et al. Effective immunoconjugate therapy in cancer models targeting a serine protease of tumor fibroblasts. Clin Cancer Res. 2008;14:584–4592.•• An important paper describing the anticancer effect of FAP-α-targeted prodrugs.
166. Fang J, Xiao L, Joo KI, et al. A potent immunotoxin targeting activation protein for treatment of breast cancer in mice. Int J Cancer. 2015;138:1013–1023.
167. Fang J, Hu B, Zhang C, et al. A multi-antigen vaccine in combination with an immunotoxin targeting tumor-associated fibroblast for treating murine melanoma. Mol Therap Oncolytics. 2016;3:16007.
168. Yi YM, Zhang G, Zeng J, et al. A new tumor vaccine:fAPtau-MT elicits effective antitumor response by targeting indolamine-2,3-dioxygenase in antigen presenting cells. Cancer Biol Ther. 2011;11:866–873.
169. Burckhart T, Thiel M, Nishikawa H, et al. Tumor-specific crosslinking of GITR as costimulation for immunotherapy. J Immunother. 2010;33:925–934.
170. Kakarla S, Chow KKH, Mata M, et al. Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma. Mol Ther. 2013;21:1611–1620.
171. Tran E, Chinnasamy D, Yu Z, et al. Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia. J Exp Med. 2013;210:125–1135.•• An important paper describing the anticancer effect of FAP-α-targeted immunotherapeutics.
172. Roberts EW, Deonarine A, Jones JO, et al. Depletion of stromal cells expressing fibroblast activation protein-α from skeletal muscle and bone marrow results in cachexia and anemia. J Exp Med. 2013;210:1137–1151.
173. Cai F, Li Z, Wang C, et al. Short hairpin RNA targeting fibroblast activation protein inhibits tumor growth and improves the tumor microenvironment in a mouse model. BMB Reports. 2013;46:252–257.
174. Rovedatti L, Di Sabatino A, Knowles CH, et al. Fibroblast activation protein expression in Crohn’s disease strictures. Inflamm Bowel Dis. 2011;17:1251–1253.